The FDA Finds no Adverse Cardiac Events with Entacapone (Stalevo)

The FDA has found after an investigation that there are no cardiac events associated with entacapone (a component of Stalevo).  

To read more books and articles by Michael S. Okun MD check Twitter @MichaelOkun and these websites with blogs and information on his books and http://parkinsonsecrets.com/ #EndingPD and https://www.tourettetreatment.com/